CZ299311B6 - Nová krystalická forma hydrochloridu 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenu - Google Patents

Nová krystalická forma hydrochloridu 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenu Download PDF

Info

Publication number
CZ299311B6
CZ299311B6 CZ20002716A CZ20002716A CZ299311B6 CZ 299311 B6 CZ299311 B6 CZ 299311B6 CZ 20002716 A CZ20002716 A CZ 20002716A CZ 20002716 A CZ20002716 A CZ 20002716A CZ 299311 B6 CZ299311 B6 CZ 299311B6
Authority
CZ
Czechia
Prior art keywords
estrogen
phenoxy
compound
water
piperidin
Prior art date
Application number
CZ20002716A
Other languages
Czech (cs)
English (en)
Other versions
CZ20002716A3 (en
Inventor
Kay Bush@Julie
Charles Conrad@Preston
Gerard Flom@Merlyn
Douglas Luke@Wayne
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CZ20002716A3 publication Critical patent/CZ20002716A3/cs
Publication of CZ299311B6 publication Critical patent/CZ299311B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20002716A 1999-07-29 2000-07-24 Nová krystalická forma hydrochloridu 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenu CZ299311B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (2)

Publication Number Publication Date
CZ20002716A3 CZ20002716A3 (en) 2001-05-16
CZ299311B6 true CZ299311B6 (cs) 2008-06-18

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20002716A CZ299311B6 (cs) 1999-07-29 2000-07-24 Nová krystalická forma hydrochloridu 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenu

Country Status (45)

Country Link
EP (1) EP1204656A2 (el)
JP (1) JP2001064277A (el)
KR (1) KR100697177B1 (el)
CN (1) CN1138770C (el)
AR (1) AR031073A1 (el)
AT (1) AT502318A1 (el)
AU (1) AU6335600A (el)
BE (1) BE1013411A3 (el)
BR (1) BR0003209A (el)
CA (1) CA2314682A1 (el)
CO (1) CO5180570A1 (el)
CZ (1) CZ299311B6 (el)
DE (1) DE10036854A1 (el)
DK (1) DK200001151A (el)
DZ (1) DZ3060A1 (el)
FI (1) FI20001722A (el)
FR (1) FR2796944B1 (el)
GB (1) GB2352717A (el)
GR (1) GR1004084B (el)
HK (1) HK1035370A1 (el)
HR (1) HRP20000503B1 (el)
HU (1) HUP0003001A2 (el)
ID (1) ID27078A (el)
IL (1) IL137553A (el)
IT (1) IT1318660B1 (el)
LT (1) LT4790B (el)
LU (1) LU90617B1 (el)
LV (1) LV12623B (el)
MD (1) MD2336G2 (el)
MX (1) MXPA00007461A (el)
MY (1) MY128764A (el)
NL (1) NL1015821C2 (el)
NO (1) NO20003879L (el)
PE (1) PE20010385A1 (el)
PL (1) PL341749A1 (el)
PT (1) PT102502A (el)
RO (1) RO121851B1 (el)
SE (1) SE0002792L (el)
SG (1) SG91296A1 (el)
SI (1) SI20426A (el)
SV (1) SV2002000132A (el)
TR (1) TR200002206A2 (el)
TW (1) TWI276437B (el)
UA (1) UA72885C2 (el)
WO (1) WO2001009116A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
HUP0302190A3 (en) * 2000-05-08 2009-03-30 Lilly Co Eli Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DK1773811T3 (da) * 2004-07-22 2010-12-13 Lilly Co Eli Krystallinsk variabelt hydrat af (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amin)-2-methylpropyl)phenoxy)-3-pyridincarboxamid-hemisuccinatsalt

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729956A1 (en) * 1995-02-28 1996-09-04 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
WO1998045287A1 (en) * 1997-04-09 1998-10-15 Eli Lilly And Company Treatment of central nervous system disorders with selective estrogen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729956A1 (en) * 1995-02-28 1996-09-04 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
WO1998045287A1 (en) * 1997-04-09 1998-10-15 Eli Lilly And Company Treatment of central nervous system disorders with selective estrogen receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rabasseda X. et al.: Drugs of the Future 1999, 24(6), 599-604 cely dokument, str. 599 sl. 2; str. 602, tab. I, pr.8 *

Also Published As

Publication number Publication date
AU6335600A (en) 2001-02-19
CZ20002716A3 (en) 2001-05-16
HK1035370A1 (en) 2001-11-23
DE10036854A1 (de) 2001-03-01
MXPA00007461A (es) 2004-07-16
ITMI20001759A0 (it) 2000-07-28
UA72885C2 (uk) 2005-05-16
CN1288007A (zh) 2001-03-21
IL137553A0 (en) 2001-07-24
MD2336G2 (ro) 2004-06-30
CO5180570A1 (es) 2002-07-30
PT102502A (pt) 2001-01-31
FR2796944A1 (fr) 2001-02-02
HRP20000503A2 (en) 2001-06-30
HUP0003001A2 (hu) 2002-04-29
MY128764A (en) 2007-02-28
WO2001009116A2 (en) 2001-02-08
SE0002792D0 (sv) 2000-07-28
LV12623B (en) 2001-07-20
FI20001722A0 (fi) 2000-07-28
NL1015821A1 (nl) 2001-01-30
FR2796944B1 (fr) 2003-01-31
NO20003879D0 (no) 2000-07-28
LV12623A (en) 2001-03-20
BR0003209A (pt) 2001-03-20
SI20426A (sl) 2001-06-30
HRP20000503B1 (en) 2008-04-30
BE1013411A3 (fr) 2001-12-04
SE0002792L (sv) 2001-01-30
LT4790B (lt) 2001-05-25
CN1138770C (zh) 2004-02-18
DZ3060A1 (fr) 2004-05-22
DK200001151A (da) 2001-01-30
TWI276437B (en) 2007-03-21
JP2001064277A (ja) 2001-03-13
CA2314682A1 (en) 2001-01-29
RO121851B1 (ro) 2008-06-30
FI20001722A (fi) 2001-01-30
LT2000076A (lt) 2001-02-26
ID27078A (id) 2001-02-22
IL137553A (en) 2005-09-25
MD20000162A (en) 2001-04-30
NO20003879L (no) 2001-01-30
TR200002206A2 (tr) 2001-03-21
SG91296A1 (en) 2002-09-17
AT502318A1 (de) 2007-02-15
LU90617B1 (fr) 2001-06-15
IE20000605A1 (en) 2001-04-04
SV2002000132A (es) 2002-06-07
AR031073A1 (es) 2003-09-10
GB2352717A (en) 2001-02-07
NL1015821C2 (nl) 2002-01-03
ITMI20001759A1 (it) 2002-01-28
GR20000100265A (el) 2001-03-30
KR100697177B1 (ko) 2007-03-21
EP1204656A2 (en) 2002-05-15
IT1318660B1 (it) 2003-08-27
MD2336F2 (en) 2003-12-31
WO2001009116A3 (en) 2001-05-17
GR1004084B (el) 2002-12-11
GB0018641D0 (en) 2000-09-13
KR20010049916A (ko) 2001-06-15
HU0003001D0 (en) 2000-10-28
PL341749A1 (en) 2001-02-12
PE20010385A1 (es) 2001-04-06

Similar Documents

Publication Publication Date Title
KR100733094B1 (ko) 6-히드록시-3-(4-[2-(피페리딘-1-일)에톡시]-페녹시)-2-(4-메톡시페닐)벤조[ｂ]티오펜 히드로클로라이드의 신규한결정형태
CZ299311B6 (cs) Nová krystalická forma hydrochloridu 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenu
US6610706B1 (en) Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AU780211B2 (en) Crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
CZ20031098A3 (cs) Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
RU2240318C2 (ru) Новая кристаллическая форма 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил) бензо[b]тиофена гидрохлорида
RU2240319C2 (ru) Новая кристаллическая форма 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил) бензо[b]тиофена гидрохлорида
IE83296B1 (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
NZ506046A (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methanoxyphenyl)benzo[b]thiophene hydrochloride
IE84089B1 (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1- yl)ethoxy]phenoxy)-2-(4- methoxyphenyl)benzo[b]thiophene hydrochloride

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20090724